A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo Mgodi, Precious Garnett, Emily Shava et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 45
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly Karuna et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2021Cited by 26
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodyDavid Burns, Gail Broder, John Hural et al.|UNC Libraries|2023Cited by 0
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsMark Anderson, Michal Juraska, Simbarashe Takuva et al.|UNC Libraries|2023Cited by 0